LIG4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17927035	0.71	1/20
SCHEMBL17927036	0.71	1/20
SCHEMBL29374901	0.71	1/20
SCHEMBL22506412	0.69	1/20
SCHEMBL22506486	0.63	1/20
SCHEMBL3666434	0.56	1/20
SCHEMBL4407466	0.55	1/20
SCHEMBL7436514	0.55	1/20
SCHEMBL21946635	0.52	1/20
SCHEMBL7443806	0.51	1/20
SCHEMBL7443811	0.51	1/20
SCHEMBL22105776	0.51	1/20
SCHEMBL11740275	0.43	1/20
SCHEMBL14129043	0.42	1/20
SCHEMBL5081727	0.40	1/20
SCHEMBL5081728	0.40	1/20
SCHEMBL9723541	0.40	1/20
SCHEMBL11418715	0.40	1/20
SCHEMBL17973873	0.40	1/20
SCHEMBL28599218	0.40	1/20

Clinical trials — most relevant to LIG4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Chromosomal Translocations in Chandigarh Police	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis	nan	COMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer	nan	RECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia	nan	COMPLETED
DNA Repair in Patients With Stable Angina.	nan	UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
Telomere Repair Gene Mutation in Inflammatory Bowel Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a LIG4 binder may also engage these)

Protein	Name	Similarity
Q5R6L3	—	1.000	Q5R6L3 →
G3GTP0	—	1.000	G3GTP0 →
Q90YB1	—	1.000	Q90YB1 →
Q8BTF7	—	1.000	Q8BTF7 →
Q5BH83	—	0.988	Q5BH83 →
A0A7H0DNE6	—	0.988	A0A7H0DNE6 →
Q2U6A1	—	0.988	Q2U6A1 →
P0DOO4	—	0.988	P0DOO4 →
P0DOO3	—	0.988	P0DOO3 →
Q67480	—	0.987	Q67480 →
Q6C8A3	—	0.987	Q6C8A3 →
P31669	—	0.987	P31669 →
O57250	—	0.987	O57250 →
LIG3	DNA ligase 3	0.986	landscape →
Q1DKE7	—	0.986	Q1DKE7 →
Q11208	—	0.985	Q11208 →
Q0UCI9	—	0.984	Q0UCI9 →
A8N936	—	0.984	A8N936 →
P37202	—	0.984	P37202 →
O74833	—	0.984	O74833 →
P42348	—	0.984	P42348 →
A2RUV5	—	0.984	A2RUV5 →
Q7Z7W5	—	0.984	Q7Z7W5 →
USP7	Ubiquitin carboxyl-terminal hydrolase 7	0.983	landscape →
Q803R5	—	0.983	Q803R5 →
P97386	—	0.983	P97386 →
Q4VSI4	—	0.983	Q4VSI4 →
Q86T65	—	0.983	Q86T65 →
Q6U7I1	—	0.983	Q6U7I1 →
P27008	—	0.983	P27008 →